| Patent Number | Title | Applicant | Opposition Date |
|---|---|---|---|
| EP3609497 | Combination Therapy For Prostate Cancer | JANSSEN PHARMACEUTICA NV | Jul 6, 2023 |
| EP3679922 | Syringe | NOVARTIS AG | Apr 28, 2023 |
| EP2981255 | Therapeutic Uses Of Empagliflozin | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | Apr 20, 2023 |
| EP2653873 | Compositions And Uses For Treating Multiple Sclerosis | BIOGEN IDEC MA INC. | Mar 6, 2023 |
| EP3033086 | Combination Therapy For The Treatment Of Cancer | NOVARTIS AG | Jun 20, 2022 |
| EP3692983 | Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof | CELGENE CORPORATION | May 10, 2022 |
| EP3434265 | Pharmaceutical Composition Containing Rifaximin Alpha & Delta | SANDOZ AG | Apr 7, 2022 |
| EP3592391 | Pharmaceutical Composition Comprising Selexipag | ACTELION PHARMACEUTICALS LTD | Jan 12, 2022 |
| EP2863895 | Tablet Formulation Comprising A Peptide And A Delivery Agent | NOVO NORDISK A/S | Jan 11, 2022 |
| EP3329909 | Fenfluramine For Use In The Treatment Of Dravet Syndrome | KATHOLIEKE UNIVERSITEIT LEUVEN KU LEUVEN RESEARCH & DEVELOPMENT | Dec 16, 2021 |
| Patent Number | Grant Date | Title | Total Oppositions |
|---|---|---|---|
| EP3050556 | Mar 22, 2017 | Process For Manufacturing A Pharmaceutical Preparation Containing Glatiramer Acetate | 2 |
Feel free to send us a message here and we will get back to you